[go: up one dir, main page]

PE20040131A1 - Formulaciones y formas de dosificacion para la administracion controlada de topiramato - Google Patents

Formulaciones y formas de dosificacion para la administracion controlada de topiramato

Info

Publication number
PE20040131A1
PE20040131A1 PE2003000750A PE2003000750A PE20040131A1 PE 20040131 A1 PE20040131 A1 PE 20040131A1 PE 2003000750 A PE2003000750 A PE 2003000750A PE 2003000750 A PE2003000750 A PE 2003000750A PE 20040131 A1 PE20040131 A1 PE 20040131A1
Authority
PE
Peru
Prior art keywords
topiramate
dosage forms
release
polyoxyl
stearate
Prior art date
Application number
PE2003000750A
Other languages
English (en)
Inventor
Shaoling Li
Winnie To
David Edgren
Robert Skluzacek
Andrew Lam
Atul D Ayer
Shu Li
Patrick S L Wong
Frank Jao
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of PE20040131A1 publication Critical patent/PE20040131A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

QUE COMPRENDE: 1)DE 50% A 60% DE UN AGENTE ACTIVO QUE ES TOPIRAMATO, CUYA DOSIS APROXIMADA ES DE 10 mg A 750 mg; 2)DE 5% A 15% DE UN PORTADOR POLIMERICO ESTRUCTURAL, QUE PUEDE SER OXIDO DE POLIETILENO DE PESO MOLECULAR ENTRE 100 000 Y 200 000; Y, 3)DE 5% A 15% DE UN SURFACTANTE SOLUBILIZANTE, ADAPTADO PARA LIBERAR EL TOPIRAMATO POR UN PERIODO DE TIEMPO PROLONGADO, EL CUAL ES SELECCIONADO DE ESTEARATO DE POLIOXILO 40, ESTEARATO DE POLIOXILO 50, POLOXAMEROS Y COPOLIMEROS DE TRES BLOQUES COMO OXIDO DE ETILENO:OXIDO DE PROPILENO:OXIDO DE ETILENO. SE REFIERE TAMBIEN A FORMAS DE DOSIFICACION DE LIBERACION CONTROLADA TALES COMO SISTEMA DE MATRIZ, SISTEMA OSMOTICO. SE REFIERE TAMBIEN A FORMAS DE DOSIFICACION ORALES QUE COMPRENDEN: a)UN NUCLEO, QUE A SU VEZ INCLUYE: i)TOPIRAMATO; ii)UN POLIMERO ESTRUCTURAL; iii)UN SURFACTANTE SOLUBILIZANTE; b)UNA MEMBRANA SEMIPERMEABLE QUE RODEA POR LO MENOS PARCIALMENTE A (a); Y, c)UN ORIFICIO DE SALIDA A TRAVES DE (b) QUE SE COMUNICA CON (a), A FIN DE PERMITIR LA LIBERACION DE (i)
PE2003000750A 2002-07-29 2003-07-30 Formulaciones y formas de dosificacion para la administracion controlada de topiramato PE20040131A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39999302P 2002-07-29 2002-07-29
US46851903P 2003-05-07 2003-05-07

Publications (1)

Publication Number Publication Date
PE20040131A1 true PE20040131A1 (es) 2004-03-06

Family

ID=31191336

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000750A PE20040131A1 (es) 2002-07-29 2003-07-30 Formulaciones y formas de dosificacion para la administracion controlada de topiramato

Country Status (12)

Country Link
US (1) US20040115262A1 (es)
EP (1) EP1534238A1 (es)
JP (1) JP2005536568A (es)
AR (1) AR040722A1 (es)
AU (1) AU2003256848A1 (es)
CA (1) CA2494233A1 (es)
MX (1) MXPA05001184A (es)
NZ (1) NZ537543A (es)
PE (1) PE20040131A1 (es)
TW (1) TW200410728A (es)
UY (1) UY27908A1 (es)
WO (1) WO2004010970A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175690A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP2186510B1 (en) * 2003-03-26 2013-07-10 Egalet Ltd. Matrix compositions for controlled delivery of drug substances
DE602004031096D1 (de) 2003-03-26 2011-03-03 Egalet As Morphin-system mit kontrollierter freisetzung
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
JP2007503389A (ja) * 2003-08-22 2007-02-22 アルザ・コーポレーシヨン 長期間にわたるトピラメートの段階的送達
EP1701697A2 (en) * 2003-09-02 2006-09-20 ALZA Corporation Novel drug compositions and dosage forms of topiramate
EP2184058B1 (en) 2003-09-26 2012-02-08 ALZA Corporation Drug coating providing high drug loading and methods for providing the same
US20070259033A1 (en) * 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
US20050129765A1 (en) * 2003-11-14 2005-06-16 Shaoling Li Controlled release of topiramate in liquid dosage forms
WO2005065648A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms of topiramate
JP2007517062A (ja) * 2003-12-29 2007-06-28 アルザ・コーポレーシヨン 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング
EP1750678A2 (en) * 2004-05-21 2007-02-14 Alza Corporation Dosage form for delivery of multiple drug forms
WO2006007323A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
US20070224281A1 (en) * 2004-07-22 2007-09-27 Amorepacific Corporation Sustained-Release Preparations Containing Topiramate and the Producing Method Thereof
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006026504A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20060165798A1 (en) * 2005-01-27 2006-07-27 Edgren David E Oral osmotic dosage form having a high flux membrane
IS7748A (is) * 2005-03-17 2006-09-18 Actavis Group Samsetning fyrir töflur sem innihalda topiramate
US20080318910A1 (en) * 2005-10-04 2008-12-25 Mistral Pharma, Inc. Controlled-Release Oral Dosage Form
US20070190137A1 (en) * 2005-10-07 2007-08-16 Reyes Iran Osmotic dosage form with controlled release and fast release aspects
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
GB2443738A (en) * 2006-11-09 2008-05-14 Proprius Pharmaceuticals Inc A sustained release methotrexate composition and methods of use thereof
EP1973528B1 (en) 2006-11-17 2012-11-07 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
WO2008070670A2 (en) * 2006-12-04 2008-06-12 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP2403487A2 (en) 2009-03-04 2012-01-11 Fdc Limited Oral controlled release dosage forms for water soluble drugs
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR20240162165A (ko) 2017-06-02 2024-11-14 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
CN115318353B (zh) * 2022-08-31 2023-09-22 江苏举世检测有限公司 一种应用于管、瓶类卷口容器的恒温水浴锅及使用方法
KR20250160703A (ko) 2024-05-07 2025-11-14 주식회사 인트로바이오파마 이중방출 기전을 갖는 토피라메이트 서방정

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US488168A (en) * 1892-12-13 Furnace for burning garbage
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (es) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) * 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4207893A (en) * 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US4957494A (en) * 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US4961932A (en) * 1987-10-26 1990-10-09 Alza Corporation Plurality of tiny pills in liquid dosage form
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5262171A (en) * 1991-11-25 1993-11-16 Isp Investments Inc. Pharmaceutical tablet with PVP having enhanced drug dissolution rate
US5413672A (en) * 1992-07-22 1995-05-09 Ngk Insulators, Ltd. Method of etching sendust and method of pattern-etching sendust and chromium films
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DK1035834T3 (da) * 1997-12-05 2002-07-08 Alza Corp Osmotisk doseringsform omfattende en første og anden coating
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
EP1652516A3 (en) * 1998-11-02 2006-05-17 ALZA Corporation Osmotic controlled delivery of active agents
WO2000025790A1 (en) * 1998-11-02 2000-05-11 Alza Corporation Controlled delivery of antidepressants
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1187604A4 (en) * 1999-05-28 2004-02-11 Jeffrey Berlant CONNECTIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS FAILURES
US6562375B1 (en) * 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6946243B2 (en) * 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
WO2002044276A2 (en) * 2000-11-28 2002-06-06 Focal, Inc. Polyalkylene glycol viscosity-enhancing polymeric formulations
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
PT1377430E (pt) * 2001-04-10 2005-11-30 Soplar Sa Dispositivo para a fabricacao de corpos ocos de material plastico num processo de extrusao por sopragem
WO2003004009A1 (en) * 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
ES2305434T3 (es) * 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement

Also Published As

Publication number Publication date
AR040722A1 (es) 2005-04-20
WO2004010970A1 (en) 2004-02-05
AU2003256848A1 (en) 2004-02-16
UY27908A1 (es) 2003-11-28
US20040115262A1 (en) 2004-06-17
CA2494233A1 (en) 2004-02-05
EP1534238A1 (en) 2005-06-01
NZ537543A (en) 2007-08-31
JP2005536568A (ja) 2005-12-02
TW200410728A (en) 2004-07-01
MXPA05001184A (es) 2005-09-12

Similar Documents

Publication Publication Date Title
PE20040131A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
PE20030519A1 (es) Forma de dosificacion, dispositivo y metodos de tratamiento
PE20050728A1 (es) Forma de dosificacion a prueba de abuso
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
AR073793A1 (es) Formulacion farmaceutica liquida que contiene paracetamol. excipiente liquido
AR038575A1 (es) Formulacion oftalmica con nueva composicion de goma
AR065073A2 (es) Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo
AR051969A1 (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central
DE60312523D1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
PE20040103A1 (es) Metodo y formas de dosificacion para incrementar la solubilidad de composiciones de farmaco para administracion controlada
CO5570662A2 (es) Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo
AR040245A1 (es) Formas de dosificacion y composiciones para administracion osmotica de dosificaciones variables de oxicodone
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
PE20010625A1 (es) Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
DE60005819D1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
DOP2010000253A (es) Sistema de administracion de drogas con efecto estabilizante
AR013117A1 (es) Una composicion farmaceutica solida en forma de comprimido que comprende un derivado de benzofurano con actividad antiarritmica adaptada para administracion oral
MX2018003028A (es) Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc).
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
AR034493A1 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
AR033596A1 (es) Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno

Legal Events

Date Code Title Description
FC Refusal